Drugmaker Valeant faces debt default risk; shares plunge 50 percent

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Drugmaker Valeant faces debt default risk; shares plunge 50 percent

CIBC Downgrades Valeant Pharmaceuticals (VRX) to Sector Underperform

March 15, 2016 5:38 PM EDT

CIBC downgraded Valeant Pharmaceuticals (NYSE: VRX) from Sector Perform to Sector Underperform with a price target of $24.00 (from $90.00).

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $69.04 yesterday.

... More

UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight

March 15, 2016 11:15 AM EDT

(Updated - March 15, 2016 11:20 AM EDT)

Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underweight. Analyst David Amsellem called Valeant a "broken company" and noted trouble spots across a number of segments.

Amsellem explained the downgrade, "VRX reported 4Q15 adjusted... More

Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat

March 15, 2016 10:56 AM EDT

Evercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.

"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.

".. today's results suggests that while... More